Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07342881 · ClinicalTrials.gov registry record · Phase 1
Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
A Phase 1 study of Chronic Hepatitis B Infection, sponsored by Aligos Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT07342881 is a Phase 1 study of Chronic Hepatitis B Infection that is actively recruiting participants, run by Aligos Therapeutics. The registered enrollment target is 30 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT07342881, a Phase 1 study of Chronic Hepatitis B Infection, is actively recruiting participants, sponsored by Aligos Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for age, body weight and, to the extent possible, for sex.
Conditions Studied
Interventions
- DRUG Pevifoscorvir Sodium (ALG-000184)
Study Locations (2)
Florida
- Orlando Clinical Research Center - Orlando
- Genesis Clinical Trials - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-02-20 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07342881
The ClinicalTrials.gov registry entry for NCT07342881 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aligos Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis B Infection appearing as the primary indexed condition, and to 1 intervention - of which Pevifoscorvir Sodium (ALG-000184) is the first listed.
NCT07342881 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07342881 about?
NCT07342881 is a clinical study titled "Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function". This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and...
What is the current status of trial NCT07342881?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-02-20. Estimated completion is 2026-07-01.
What conditions does trial NCT07342881 study?
This clinical trial studies the following conditions: Chronic Hepatitis B Infection.
What interventions are being tested in trial NCT07342881?
The interventions under investigation include: Pevifoscorvir Sodium (ALG-000184) (DRUG).
Who is sponsoring clinical trial NCT07342881?
This trial is sponsored by Aligos Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07342881 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis B Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.